References
- Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657–3669.
- Kota SK, Jammula S, Kota SK, et al. Necrobiosis lipoidica diabeticorum: a case-based review of literature. Indian J Endocrinol Metab. 2012;16(4):614–620.
- Dogramaci AC, Savas N, Ozer B, et al. Skin diseases in patients with β-thalassemia major. Int J Dermatol. 2009;48(10):1057–1061.
- Fahmey SS, Taha G, El-Refaey A, et al. Disorders in Egyptian children with β-thalassemia major. J Trop Pediatr. 2018;64(2):104–109.
- El-Dash H, Adel S. Cutaneous manifestations in Egyptian children with β-thalassemia major: relationship with serum ferritin, thyroid profile, and treatment modalities. Pediatr Dermatol. 2018;35(5):639–643.
- Mobarra N, Shanaki M, Ehteram H, et al. A review on iron chelators in treatment of iron overload syndromes. Int J Hematol Oncol Stem Cell Res. 2016;10(4):239–247.
- Bucak IH, Almis H, Benli S, et al. The assessment of skin color and iron levels in pediatric patients with β-thalassemia major using a visual skin color chart. Hemoglobin. 2017;41(2):120–123.
- Graudal C, Andersen AR, Lange K, et al. Necrobiosis lipoidica in a patient with bronze diabetes. Hautarzt. 1984;35(8):418–420. [German]
- Skandalis K, Vlachos C, Pliakou X, et al. Higher serum ferritin levels correlate with an increased risk of cutaneous morbidity in adult patients with β-thalassemia: a single-center retrospective study. Acta Haematol. 2016;135(2):124–130.
- Bickers DR, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol. 2006;126(12):2565–2575.
- Erfurt-Berge C, Sticherling M. Successful treatment of ulcerative necrobiosis lipoidica with janus kinase inhibitor. J Eur Acad Dermatol Venereol. 2020. Online ahead of print. DOI:10.1111/jdv.16297
- Taher AT, Karakas Z, Cassinerio E, et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood. 2018;131(2):263–265.